Year 2018: top* 10 papers with the highest R-portion

Topic: Cancer Immunotherapy

* The top 5% of entries has been removed to reduce statistical anomalies. Further fine-tuning, filtering, and error cleaning are in progress.

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints

YCR = 2018 / 365 /  14.32 

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

YCR = 2018 / 456 /  14.17 

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

YCR = 2018 / 470 /  13.45 

Comprehensive analysis of the clinical immuno-oncology landscape

YCR = 2018 / 429 /  13.27 

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

YCR = 2018 / 410 /  13.06 

CHECKPOINT INHIBITOR IMMUNE THERAPY

YCR = 2018 / 251 /  13.04 

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

YCR = 2018 / 502 /  13.00 

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

YCR = 2018 / 348 /  12.67 

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

YCR = 2018 / 449 /  12.66 

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

YCR = 2018 / 498 /  12.54